ScoreComparison
Why is Fate Therapeutics, Inc. ?
1
Poor long term growth as Operating profit has grown by an annual rate -12.52% of over the last 5 years
2
Flat results in Jun 25
- NET SALES(Q) At USD 1.91 MM has Fallen at -42.8%
- RAW MATERIAL COST(Y) Grown by 348.86% (YoY)
- CASH AND EQV(HY) Lowest at USD 463.25 MM
3
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -36.75%, its profits have risen by 13.6%
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -36.75% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Fate Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Fate Therapeutics, Inc.
-36.75%
-0.73
99.98%
S&P 500
16.49%
0.83
19.88%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-8.51%
EBIT Growth (5y)
-12.52%
EBIT to Interest (avg)
-209.26
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.81
Sales to Capital Employed (avg)
0.12
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.64
EV to EBIT
0.27
EV to EBITDA
0.30
EV to Capital Employed
-0.93
EV to Sales
-3.78
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-56.74%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend10What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -115.62 MM
OPERATING PROFIT(Q)
Highest at USD -33.69 MM
PRE-TAX PROFIT(Q)
Highest at USD -34 MM
NET PROFIT(Q)
Highest at USD -34 MM
EPS(Q)
Highest at USD -0.29
-14What is not working for the Company
NET SALES(Q)
At USD 1.91 MM has Fallen at -42.8%
RAW MATERIAL COST(Y)
Grown by 348.86% (YoY
CASH AND EQV(HY)
Lowest at USD 463.25 MM
DEBTORS TURNOVER RATIO(HY)
Lowest at 2.76 times
Here's what is working for Fate Therapeutics, Inc.
Operating Cash Flow
Highest at USD -115.62 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Operating Profit
Highest at USD -33.69 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD -34 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -34 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -0.29
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Here's what is not working for Fate Therapeutics, Inc.
Net Sales
At USD 1.91 MM has Fallen at -42.8%
over average net sales of the previous four periods of USD 3.33 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (USD MM)
Cash and Eqv
Lowest at USD 463.25 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debtors Turnover Ratio
Lowest at 2.76 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
Raw Material Cost
Grown by 348.86% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
